Comparison · NCT04631016-sae
Tozorakimab vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tozorakimab vs Placebo: serious adverse events. Trial comparisons, record NCT04631016-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04631016-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.209 | 0.129 | 0.321 | wilson | |
| Risk in group 2 | 0.132 | 0.0712 | 0.233 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0766 | -0.0519 | 0.204 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.58 | 0.734 | 3.4 | log | |
| Odds ratio, group 1 over group 2 | 1.73 | 0.693 | 4.33 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Tozorakimab than on Placebo | 13.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tozorakimab | Participants received 7 doses of subcutaneous (SC) tozorakimab Dose Level 1 injection once every 4 weeks (Q4W). | 14 | 67 | EG000 |
| Group 2 | Placebo | Participants received 7 doses of SC placebo injection matched to tozorakimab once Q4W. | 9 | 68 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 through 253 days (maximum observed duration)
Source ClinicalTrials.gov
Trial
- Title
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
- NCT number
- NCT04631016
- Phases
- PHASE2
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis
- Interventions
- Tozorakimab, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2025-02-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04631016?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04631016-sae